PMC:7795856 / 20693-22034 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"359","span":{"begin":389,"end":404},"obj":"Gene"},{"id":"360","span":{"begin":418,"end":444},"obj":"Gene"},{"id":"361","span":{"begin":446,"end":449},"obj":"Gene"},{"id":"362","span":{"begin":463,"end":482},"obj":"Gene"},{"id":"363","span":{"begin":484,"end":487},"obj":"Gene"},{"id":"364","span":{"begin":512,"end":535},"obj":"Gene"},{"id":"365","span":{"begin":537,"end":542},"obj":"Gene"},{"id":"366","span":{"begin":1020,"end":1042},"obj":"Gene"},{"id":"367","span":{"begin":1044,"end":1050},"obj":"Gene"},{"id":"368","span":{"begin":1090,"end":1095},"obj":"Gene"},{"id":"369","span":{"begin":457,"end":462},"obj":"Species"}],"attributes":[{"id":"A359","pred":"tao:has_database_id","subj":"359","obj":"Gene:7114"},{"id":"A360","pred":"tao:has_database_id","subj":"360","obj":"Gene:4880"},{"id":"A361","pred":"tao:has_database_id","subj":"361","obj":"Gene:4880"},{"id":"A362","pred":"tao:has_database_id","subj":"362","obj":"Gene:5741"},{"id":"A363","pred":"tao:has_database_id","subj":"363","obj":"Gene:5741"},{"id":"A364","pred":"tao:has_database_id","subj":"364","obj":"Gene:2641"},{"id":"A365","pred":"tao:has_database_id","subj":"365","obj":"Gene:2641"},{"id":"A366","pred":"tao:has_database_id","subj":"366","obj":"Gene:1803"},{"id":"A367","pred":"tao:has_database_id","subj":"367","obj":"Gene:1803"},{"id":"A368","pred":"tao:has_database_id","subj":"368","obj":"Gene:2641"},{"id":"A369","pred":"tao:has_database_id","subj":"369","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The beneficial application of the PASylation technology demonstrated in this work can be transferred to other peptides. There are more than 7000 naturally occurring peptides covering a wide range of physiological functions [61], including many peptides with proven therapeutic potential, which could profit from the presented approach. Examples are therapeutically active peptides such as thymosin beta 4 [62,63], the C-type natriuretic peptide (CNP) [64], human parathyroid hormone (PTH) [65], relaxin [66], or glucagon-like peptide-1 (GLP-1) and its analogs [67]. Today, it is generally recognized that intrinsic weaknesses of this drug class, such as poor stability and short circulating plasma half-life, need to be addressed in order to transform peptides into efficacious medicines [61]. The approach described here, N- or C-terminal PASylation, optionally combined with acetylation, solves both. On the one hand, N-terminal acetylation protects peptides from proteolytic degradation by exoproteases, for example, dipeptidyl peptidase-4 (DPP-IV), as shown for N-terminally acetylated GLP-1 [68]. On the other hand, PASylation increases the hydrodynamic volume of the peptide above the pore size of the glomerular basement membrane, hence retarding kidney filtration and prolonging the pharmacodynamic effect of its fusion partner [31]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T117","span":{"begin":0,"end":119},"obj":"Sentence"},{"id":"T118","span":{"begin":120,"end":335},"obj":"Sentence"},{"id":"T119","span":{"begin":336,"end":565},"obj":"Sentence"},{"id":"T120","span":{"begin":566,"end":793},"obj":"Sentence"},{"id":"T121","span":{"begin":794,"end":902},"obj":"Sentence"},{"id":"T122","span":{"begin":903,"end":1101},"obj":"Sentence"},{"id":"T123","span":{"begin":1102,"end":1341},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The beneficial application of the PASylation technology demonstrated in this work can be transferred to other peptides. There are more than 7000 naturally occurring peptides covering a wide range of physiological functions [61], including many peptides with proven therapeutic potential, which could profit from the presented approach. Examples are therapeutically active peptides such as thymosin beta 4 [62,63], the C-type natriuretic peptide (CNP) [64], human parathyroid hormone (PTH) [65], relaxin [66], or glucagon-like peptide-1 (GLP-1) and its analogs [67]. Today, it is generally recognized that intrinsic weaknesses of this drug class, such as poor stability and short circulating plasma half-life, need to be addressed in order to transform peptides into efficacious medicines [61]. The approach described here, N- or C-terminal PASylation, optionally combined with acetylation, solves both. On the one hand, N-terminal acetylation protects peptides from proteolytic degradation by exoproteases, for example, dipeptidyl peptidase-4 (DPP-IV), as shown for N-terminally acetylated GLP-1 [68]. On the other hand, PASylation increases the hydrodynamic volume of the peptide above the pore size of the glomerular basement membrane, hence retarding kidney filtration and prolonging the pharmacodynamic effect of its fusion partner [31]."}